Targeted therapies in myeloid leukemias.

Abstract excerpt

There is still a compelling need to improve therapeutic outcome in AML. However, during the past several years our understanding of the genetic basis of AML, and the nature of the mutations that contribute to the phenotype, have been elucidated in cell culture and murine models of leukemia. The validation of various mutant leukemogenic gene products has in turn led to the development of an expanding group of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Leukemia, Myeloid
• Share to Lymphoproliferative Disorders
• Share to Multicenter Studies as Topic